Completed PHASE3 INTERVENTIONAL 2-arm NCT00255606

Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer

A Phase III Trial Comparing Docetaxel Every Third Week to Biweekly Docetaxel Monotherapy in Metastatic Hormone Refractory Prostate Cancer Patients - PROSTY Trial

Sponsor: Tampere University

Conditions Prostate Cancer

Interventions docetaxel prednisone

Updated 7 times since 2017 Last updated: Jun 25, 2013 Started: Aug 31, 2005 Primary completion: May 31, 2009 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Prostate Cancer and is currently completed. Tampere University leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Apr 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Apr 2019 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tampere University

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Cork, Ireland , Dublin, Ireland , Galway, Ireland , Helsinki, Finland , Kajaani, Finland , Karlstad, Sweden , Kokkola, Finland , Kotka, Finland , Lahti, Finland , Limerick, Ireland and 5 more locations